These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10510403)

  • 41. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
    Sethi S; Fervenza FC
    Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.
    Pangburn MK; Pangburn KL; Koistinen V; Meri S; Sharma AK
    J Immunol; 2000 May; 164(9):4742-51. PubMed ID: 10779780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
    Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
    J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
    Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
    Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification and characterization of a functional human Ig V lambda VI germline gene.
    Ch'ang LY; Yen CP; Besl L; Schell M; Solomon A
    Mol Immunol; 1994 May; 31(7):531-6. PubMed ID: 8190128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.
    Ding Y; Zhao W; Zhang T; Qiang H; Lu J; Su X; Wen S; Xu F; Zhang M; Zhang H; Zeng C; Liu Z; Chen H
    Sci Rep; 2017 Jul; 7(1):6004. PubMed ID: 28729648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isolation and characterization of a monoclonal human thyroid peroxidase autoantibody of lambda light chain type.
    Prummel MF; Portolano S; Costante G; Rapoport B; McLachlan SM
    Mol Cell Endocrinol; 1994 Jun; 102(1-2):161-6. PubMed ID: 7926268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Group A streptococcal phagocytosis resistance is independent of complement factor H and factor H-like protein 1 binding.
    Kotarsky H; Gustafsson M; Svensson HG; Zipfel PF; Truedsson L; Sjöbring U
    Mol Microbiol; 2001 Aug; 41(4):817-26. PubMed ID: 11532146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis.
    Sharma AK; Pangburn MK
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10996-1001. PubMed ID: 8855297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11.
    Jarva H; Jokiranta TS; Hellwage J; Zipfel PF; Meri S
    J Immunol; 1999 Oct; 163(7):3957-62. PubMed ID: 10490997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients.
    Zhao J; Zhang B; Zhu J; Nussinov R; Ma B
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2294-2303. PubMed ID: 29241665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative three-dimensional model of the carboxy-terminal domain of the lambda repressor and its use to build intact repressor tetramer models bound to adjacent operator sites.
    Chattopadhyaya R; Ghosh K
    J Struct Biol; 2003 Feb; 141(2):103-14. PubMed ID: 12615536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Localization of an idiotope on the L chain dimer and intact IgG1 immunoglobulin from the patient Mcg.
    Raison RL; Edmundson AB
    Mol Immunol; 1987 Sep; 24(9):937-43. PubMed ID: 3116412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.
    Spitzer RE; Stitzel AE; Tsokos GC
    Clin Immunol Immunopathol; 1990 Oct; 57(1):19-31. PubMed ID: 2394034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Three-dimensional structure of a human immunoglobulin with a hinge deletion.
    Guddat LW; Herron JN; Edmundson AB
    Proc Natl Acad Sci U S A; 1993 May; 90(9):4271-5. PubMed ID: 8483943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are nephritic factors nephritogenic?
    Mathieson PW; Peters K
    Am J Kidney Dis; 1994 Dec; 24(6):964-6. PubMed ID: 7985677
    [No Abstract]   [Full Text] [Related]  

  • 59. Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H.
    Haque A; Cortes C; Alam MN; Sreedhar M; Ferreira VP; Pangburn MK
    Front Immunol; 2020; 11():1728. PubMed ID: 32849614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.
    Ajona D; Castaño Z; Garayoa M; Zudaire E; Pajares MJ; Martinez A; Cuttitta F; Montuenga LM; Pio R
    Cancer Res; 2004 Sep; 64(17):6310-8. PubMed ID: 15342420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.